Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158266 | 0.83 | KDM4E (0.34) | KDM4EPIK3CD | |
| SCHEMBL19342028 | 0.82 | KDM4E (0.33) | KDM4EPIK3CD | |
| SCHEMBL21572217 | 0.79 | KDM4E (0.33) | KDM4EPIK3CD | |
| SCHEMBL6983526 | 0.79 | PIK3CD (0.40) | KDM4EPIK3CD | |
| SCHEMBL22546364 | 0.78 | KDM4E (0.31) | KDM4E | |
| SCHEMBL4952545 | 0.77 | PDE3B (0.40) | KDM4EPIK3CDNAAA | |
| SCHEMBL1146179 | 0.77 | KDM4E (0.35) | KDM4EPIK3CD | |
| SCHEMBL1145997 | 0.76 | KDM4E (0.37) | KDM4EPIK3CDNAAA | |
| SCHEMBL14861553 | 0.76 | CA12 (0.35) | KDM4E | |
| SCHEMBL16529574 | 0.76 | KDM4E (0.33) | KDM4EPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024220708-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | GANDEEVA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| CN-107200716-B | Benzoxazine compound and preparation method and application thereof | 北京大学 | 2020-04-17 | — | — | CN | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3312172-A1 | AMINOPYRAZOLE DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20100120753-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | disclosed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009398-A1 | p27 Protein Inducer | CDKN1A, CDK2, SKP2 | KDM4E 2542/4885PIK3CD 2114/4885NAAA 3925/4885 |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | KDM4E 903/4885PIK3CD 803/4885NAAA 3953/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | KDM4E 903/4885PIK3CD 803/4885NAAA 3953/4885 |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | NQO2, RSU1, RRS1 | KDM4E 2147/4885PIK3CD 1900/4885NAAA 2040/4885 |
| US-20100120753-A1 | Anti-Infective Agents | RSU1, NQO2, RRS1 | KDM4E 2313/4885PIK3CD 2035/4885NAAA 2067/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | KDM4E 2810/4885PIK3CD 1250/4885NAAA 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.